Medicine:Deucrictibant
From HandWiki
Deucrictibant is an investigational new drug that is being evaluated by Pharvaris for the treatment of hereditary angioedema (HAE). It is a bradykinin receptor B2 antagonist which blocks bradykinin-driven swelling attacks which is a characteristic of HAE.[1][2][3]
Deucrictibant contains a deuterium atom to stabilize it against metabolism and to prolong the half-life of the drug.[4]
Clinical trials
Deucrictibant is in phase 3 clinical trials for hereditary angioedema.[5]
References
- ↑ "Deucrictibant - Pharvaris". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800055894.
- ↑ "Non-peptide bradykinin B2 receptor ligands possessing the substituted quinolinyl moiety: Pharmacological properties and prospective clinical uses". Peptides 195. January 2026. doi:10.1016/j.peptides.2026.171466. PMID 41548609.
- ↑ "Updates on the Current and Evolving Treatment for Hereditary Angioedema". The Journal of Allergy and Clinical Immunology. In Practice 14 (2): 375–383. February 2026. doi:10.1016/j.jaip.2025.11.039. PMID 41654335.
- ↑ "The EC85 derived from the oral bradykinin B2 receptor antagonist deucrictibant (PHA121) against bradykinin effects in healthy volunteers predicts the onset and duration of its clinical effects in hereditary angioedema.". Allergy, Asthma & Clinical Immunology 19 (Suppl 1): 106. 2023. doi:10.1186/s13223-023-00845-9. PMID 38124188. PMC 10731679. https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f. "Presented at: 13th C1-Inhibitor Deficiency and Angioedema Workshop; 2023 May 4–7; Budapest, Hungary.".
- ↑ Clinical trial number NCT06669754 for "Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE" at ClinicalTrials.gov
 |  |
